Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 3, 2009, Pages 443-450

  Cambau, Emmanuelle ^a,b   Matrat, Stephanie ^c   Pan, Xiao Su ^d   Roth Dit Bettoni, Romain ^a   Corbel, Céline ^a   Aubry, Alexandra ^c,e   Lascols, Christine ^a   Driot, Jean Yves ^f   Fisher, L Mark ^d  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITY OF LONDON   (United Kingdom)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f Laboratoires Bausch and Lomb/Chauvin   (France)

Author keywords

Gyrase; Pneumococci; Resistant mutant; Staphylococci; Topoisomerase IV

Indexed keywords

BESIFLOXACIN; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; MOXIFLOXACIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG TARGETING; ENZYME ASSAY; ENZYME INHIBITION; ESCHERICHIA COLI; GENE MUTATION; IC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; AZEPINES; DNA GYRASE; DNA MUTATIONAL ANALYSIS; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 60649093308     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn528     Document Type: Article

References (51)

1. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000; 31 Suppl 2: S24-8.
2. Gellert M, Mizuuchi K, O'Dea MH et al. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci USA 1977; 74: 4772-6.
3. Khodursky AB, Zechiedrich EL, Cozzarelli NR. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci USA 1995; 92: 11801-5.
4. Ferrero L, Cameron B, Manse B et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones. Mol Microbiol 1994; 13: 641-53.
5. Barrett JF, Gootz TD, McGuirk PR et al. Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents. Antimicrob Agents Chemother 1989; 33: 1697-703.
6. Levine C, Hiasa H, Marians KJ. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim Biophys Acta 1998; 1400: 29-43.
7. Hooper D. Mechanisms of quinolone resistance. In: Hooper D, Rubinstein E, eds. Quinolone Antimicrobial Agents. Washington, DC: ASM Press, 2003; 41-67.
8. Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 1554-8.
9. Ward KW, Lepage JF, Driot JY. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther 2007; 23: 243-56.
10. Yoshida H, Bogaki M, Nakamura M et al. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 1990; 34: 1271-2.
11. Pan XS, Ambler J, Mehtar S et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40: 2321-6.
12. Pan XS, Fisher LM. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother 1997; 41: 471-4.
13. Yamagishi J, Yoshida H, Yamayoshi M et al. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet 1986; 204: 367-73.
14. Bachoual R, Tankovic J, Soussy CJ. Analysis of the mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli. Microb Drug Resist 1998; 4: 271-6.
15. Breines DM, Ouabdesselam S, Ng EY et al. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob Agents Chemother 1997; 41: 175-9.
16. Cattoir V, Lesprit P, Lascols C et al. In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid. J Antimicrob Chemother 2006; 58: 1054-7.
17. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
18. Pan XS, Fisher LM. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: Overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob Agents Chemother 1999; 43: 1129-36.
19. Hallett P, Grimshaw AJ, Wigley DB et al. Cloning of the DNA gyrase genes under tac promoter control: Overproduction of the gyrase A and B proteins. Gene 1990; 93: 139-42.
20. Blanche F, Cameron B, Bernard FX et al. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob Agents Chemother 1996; 40: 2714-20.
21. Aubry A, Veziris N, Cambau E et al. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: Functional analysis of mutant enzymes. Antimicrob Agents Chemother 2006; 50: 104-12.
22. Gilbert DN, Kohlhepp SJ, Slama KA et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob Agents Chemother 2001; 45: 883-92.
23. Schmitz FJ, Fluit AC, Brisse S et al. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol Med Microbiol 1999; 26: 281-7.
24. Alovero FL, Pan XS, Morris JE et al. Engineering the specificity of antibacterial fluoroquinolones: Benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob Agents Chemother 2000; 44: 320-5.
25. Morrissey I, George JT. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. J Antimicrob Chemother 2000; 45 Suppl 1: 101-6.
26. Yague G, Morris JE, Pan XS et al. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob Agents Chemother 2002; 46: 413-9.
27. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 410-2.
28. Otani T, Tanaka M, Ito E et al. In vitro and in vivo antibacterial activities of DK-507 k, a novel fluoroquinolone. Antimicrob Agents Chemother 2003; 47: 3750-9.
29. Hovding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008; 86: 5-17.
30. Montagnani F, Malandrini A, Stolzuoli L et al. Microbiological features of acute bacterial conjunctivitis in a central Italian area. New Microbiol 2008; 31: 291-4.
31. Morris JE, Pan XS, Fisher LM. Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: Role of the C-5 group in target specificity. Antimicrob Agents Chemother 2002; 46: 582-5.
32. Heaton VJ, Ambler JE, Fisher LM. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob Agents Chemother 2000; 44: 3112-7.
33. Kishii R, Takei M, Fukuda H et al. Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47 77-81.
34. Fisher LM, Heaton VJ. Dual activity of fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2003; 51: 463-4; author reply 464-5.
35. Smith HJ, Nichol KA, Hoban DJ et al. Dual activity of fluoroquinolones against Streptococcus pneumoniae: The facts behind the claims. J Antimicrob Chemother 2002; 49: 893-5.
36. Fournier B, Hooper DC. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: Novel pleiotropic effects on quinolone and coumarin activity. Antimicrob Agents Chemother 1998; 42: 121-8.
37. Ince D, Zhang X, Hooper DC. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47 1410-5.
38. Ince D, Zhang X, Silver LC et al. Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 274-82.
39. Ince D, Hooper DC. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45: 2755-64.
40. Strahilevitz J, Hooper DC. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: Direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother 2005; 49: 1949-56.
41. Ince D, Zhang X, Silver LC et al. Dual targeting of DNA gyrase and topoisomerase IV: Target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother 2002; 46: 3370-80.
42. Hallett P, Maxwell A. Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein: Enzymatic analysis of the mutant proteins. Antimicrob Agents Chemother 1991; 35: 335-40.
43. Hoshino K, Kitamura A, Morrissey I et al. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother 1994; 38: 2623-7.
44. Schedletzky H, Wiedemann B, Heisig P. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother 1999; 43 Suppl B: 31-7.
45. Cambau E, Bordon F, Collatz E et al. Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid. Antimicrob Agents Chemother 1993; 37: 1247-52.
46. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 1996; 40: 879-85.
47. Bagel S, Hullen V, Wiedemann B et al. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother 1999; 43: 868-75.
48. Lu T, Zhao X, Drlica K. Gatifloxacin activity against quinolone-resistant gyrase: Allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob Agents Chemother 1999; 43: 2969-74.
49. Fernandez-Moreira E, Balas D, Gonzalez I et al. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins. Microb Drug Resist 2000; 6 259-67.
50. Onodera Y, Uchida Y, Tanaka M et al. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae. J Antimicrob Chemother 1999; 44: 533-6.
51. Pan XS, Fisher LM. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2810-6.